article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

FDA Law Blog: Biosimilars

This FR Notice and draft strategy document are part of FDA’s commitment under the Prescription Drug User Fee Act (PDUFA) Reauthorization Performance Goals and Procedures for Fiscal Years 2023-2027 (PDUFA VII), wherein FDA committed to advance the use and implementation of innovative manufacturing.

FDA 57
article thumbnail

Article EMA Thank You Proposal for IVDR extension also impacts MDR, EUDAMED

Agency IQ

Class A devices needed to be IVDR-ready on the original date (May 26, 2022), but class D had until May 2025, class C until May 2026, and class B and sterile class A until May 2027. These requirements are similar to what is already required for critical pharmaceutical products. In-house tests (in the U.S. Once the E.U.

article thumbnail

How Many Clinical Trials Are Run by CROs?

Vial

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. A rise of clinical trial outsourcing due to cost management, globalization, and digitalization.

article thumbnail

Breakthrough drug candidates and cancer treatment innovations

Drug Target Review

How does Zymeworks plan to advance at least five novel medicines into clinical studies by 2027 under its ZYME 5×5 R&D objectives? We continue our in-house development strategy of accelerating our time from preclinical development candidate selection through IND filing.

Treatment 100
article thumbnail

Analysis Chemical Thank You Regulatory roundup: EU active on PFAS as Q4 commences

Agency IQ

France In January, the French ecology ministry published a PFAS action plan enumerating six objectives for regulating forever chemicals more comprehensively by 2027. In other words, the European pharmaceuticals industry could find itself directly affected rather than indirectly impacted through the supply chain.

article thumbnail

An Offer You Can’t Refuse: Merck Attacks Medicare Negotiation Program as an Unconstitutional Taking

FDA Law Blog: Biosimilars

Recall that CMS will require manufacturers of selected drugs to negotiate a maximum fair price (“MFP”) with the agency according to the following timeline (the dates apply from applicable year 2027 onwards). Complaint at 2.

article thumbnail

No Sleep ‘Til District Court: Jazz Sues FDA Over Sodium Oxybate Clinical Superiority Determination

FDA Law Blog: Biosimilars

Koblitz — Neither Jazz Pharmaceuticals nor Avadel CNS Pharmaceuticals has taken the battle of sodium oxybate—a drug approved to treat narcolepsy—lying down. After suing each other in patent litigation and Avadel’s suit against FDA challenging the Agency’s authority to compel patent certifications, it’s Jazz’s turn to sue FDA.

FDA 52